PTO/SB/08s (08-03)
Approved for use through 97/31/2006, ONE 0651-0231
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Filing Date		
	First Named Inventor	ŀ	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		
(Not for submission under 57 of K 1.33)	Examiner Name	ſ	

	Application Number		10536846		
	Filing Date		2005-05-31		
	First Named Inventor Amag		ud Bourge, et al		
	Art Unit		2183		
	Examiner Name				
	Attorney Docket Number		FR020134		

					U.S.	PATENTS			Remove	
Examiner Initial*	aminer Cite No Patent Number Kind Code1 Issue Da)ate	Name of Patentee or Applicant R			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1									
If you wis	h to a	ı dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Cite Initial* No Publication Number		Kind Code ¹	Code1 Date Name of Patentee of Applicant F		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1									
If you wis	h to a	dd additional U.S. Publi				information p		d button	Add	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	y	Kind Code ⁴	Publication	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	т
	1	EP1202577			B1	2002-05-02	KPENV			
	2	EP1202577			A9	2002-05-02	KPENV			
	3	EP1202577			A1	2002-05-02	KPENV			

	,—				-		-				-
	4	woo	120912		A1	2001-03-22	KPENV				
	5										
If you wis	h to a	dd add	fitional Foreign I	Patent Document	citation	information p	lease click the Add t	utton	Add		
				NON-PATE	NT LITI	ERATURE DO	CUMENTS		Remove		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue numt publisher, city and/or country where publishers						Тs					
H. R. WU, ET.AL: A Generalized Block-Edge Impairment Metric for Video Coding, vol. 4, no.11, November pages 317-320, IEEE SIGNAL.					November 19	997,					
If you wis	h to a	dd add	itional non-pate	nt literature docu	ment ci	tation informat	ion please click the	Add but	tton Add		_
				Đ	CAMINE	R SIGNATUR	E				
Examiner	Sign	ature					Date Consider	ed			
*EXAMIN	**EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

18e Kint Code of USPTO Petert Documents at year, USETO_GOLY or MPEP 901.04. * Enter of this that issued the document, by the involvator code (WPO) Standard 51.3.* * The planese patient comment, the indication of the part of the register present period in the memory and precede the settle number of the patient of the patient or many of the Emperor number period the extension of the patient of the patient or the patient or the patient of the patient or t

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10536846		
Filing Date		2005-05-31		
First Named Inventor Amau		d Bourge, et al		
Art Unit		2183		
Examiner Name				
Attorney Docket Number		FR020134		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the	appropriate selection(s):
---------------	--------------	------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(s)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Larry Liberchuk/	Date (YYYY-MM-DD)	2006-11-13
Name/Print	Larry Liberchuk	Registration Number	40352

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. DING YESP IEEE SING COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.